The Rel/NF-kB transcription factors regulate the expression of many genes. The activity of RelA, a member of the Rel/NF-kB transcription factor family, is constitutively activated in the majority of pancreatic adenocarcinomas and cell lines. We report that the urokinase-type plasminogen activator (uPA), one of the critical proteases involved in tumor invasion and metastasis, is overexpressed in pancreatic tumor cells and its overexpression is induced by constitutive RelA activity. The uPA promoter contains an NF-kB binding site that directly mediates the induction of uPA expression by RelA. Expression of a dominant-negative IkBa mutant inhibits kB site-dependent transcriptional activation of a uPA promoter-CAT reporter gene. Treating the pancreatic tumor cell lines with the known NF-kB inhibitors, dexamethasone and n-tosylphenyalanine chloromethyl ketone (TPCK), abolishes constitutive RelA activity and uPA overexpression. These results show that uPA is one of the downstream target genes induced by constitutively activated RelA in human pancreatic tumor cells, and suggests that constitutive RelA activity may play a critical role in tumor invasion and metastasis. Inhibition of constitutive RelA in pancreatic tumor cells may reduce their invasive and metastatic potential.
Introduction
Rel/NF-kB is a family of pleiotropic transcription factors that control the expression of numerous genes involved in the immune response, embryonic development, lymphoid dierentiation, oncogenesis and apoptosis (Verma et al., 1995; Baldwin, 1996) . The Rel/NF-kB family consists of relA (p65), c-rel, v-rel, relB, nfkb1 and nfkb2, which can form heterodimers and homodimers among themselves (Verma et al., 1995; Baldwin, 1996) . In most cell types, Rel/NF-kB proteins are sequestered in the cytoplasm in an inactive form through their noncovalent association with the inhibitor IkB (Baeuerle and Baltimore, 1988; Grilli et al., 1993) . This association masks the nuclear localization signal of Rel/NF-kB, thereby preventing Rel/NF-kB nuclear translocation (Baeuerle and Baltimore, 1988; Grilli et al., 1993) . Activation of Rel/NFkB is controlled by IkBa and does not require protein synthesis, thereby allowing rapid and ecient gene regulation (Baeuerle and Baltimore, 1988; Grilli et al., 1993; Verma et al., 1995; Baldwin, 1996) . Stimulation of cells by various inducers leads to phosphorylation of IkBa at serine residues 32 and 36, which triggers the rapid degradation of the inhibitor. Consequently, Rel/ NF-kB proteins are released and translocated into the nucleus, where they activate the expression of target genes (Brown et al., 1995; Chen et al., 1995; DiDonato et al., 1995) .
Several reports suggest that members of the Rel/NFkB and IkB families are involved in tumorigenesis and metastasis (Gilmore et al., 1997) . Carried by a highly oncogenic retrovirus, v-rel causes aggressive tumors in young birds and is able to transform avian lymphoid cells and ®broblasts (Moore and Bose, 1988a,b) . The mutated c-rel oncogene transforms cells (Sylla and Temin, 1986) . The Tax protein from the human T-cell leukemia virus (HTLV-1) is a potent activator of Rel/ NF-kB, and the growth of Tax-induced tumors in mice is inhibited by antisense RelA constructs (Kitajima et al., 1992) . Furthermore, the expression of IkBa antisense results in constitutive activation of RelA and oncogenic transformation of NIH3T3 cells (Beauparlant et al., 1994) , suggesting that RelA is a proto-oncogene. The genes encoding c-Rel, Bcl-3, p105 (p50) and p100 (p52) have been shown to be located at sites of recurrent genomic rearrangements in lymphoid cancers (Ohno et al., 1990; Lu et al., 1991; Neri et al., 1991; Liptay et al., 1992; Gilmore et al., 1997) . It has been shown that NF-kB can regulate the expression of several genes important to cellular adhesion (i.e. genes encoding ICAM-I, ELAM-I, VCAM-I and type IV collagenase) (Voraberger et al., 1991; Whelan et al., 1991; Ghersa et al., 1992; Sato and Seiki, 1993; Iademarco et al., 1992) . These results suggest that a dysregulation of NF-kB activity in tumor cells could lead to tumorigenesis and promote the development of metastasis.
The expression of urokinase-type plasminogen activator (uPA) can be regulated by ras (Testa et al., 1989; Stacey et al., 1991) , by the tyrosine kinaseencoding oncogenes v-src and v-yes (Bell et al., 1990 (Bell et al., , 1993 , by the serine-threonine kinase-encoding v-mos oncogene (Lengyel et al., 1995b) and by polyomavirus middle-T antigen (Besser et al., 1995b) . uPA is a serine protease that cleaves extracellular matrix/basement membrane (ECM/BM) proteins (e.g. ®bronectin, laminin and collagen) directly; it also can degrade ECM/BM proteins by converting the ubiquitous extracellular zymogen plasminogen into plasmin, another serine protease with broader proteolytic activity. Subsequently, plasmin can convert procollagenases into collagenases necessary for the degradation of basement membrane collagen and can activate metalloproteinases, another class of proteases with more potent ECM/BM-degrading capability (Dano et al., 1985; Pollanen et al., 1991; Birkedal-Hansen et al., 1993; Stetler-Stevenson et al., 1993) . Thus, overexpression of uPA by neoplastic cells at the invading front of cancerous tissue leads to a cascade of proteolytic activities critical to local tumor growth and metastasis (Ginestra et al., 1997) .
Little information is available concerning the expression and regulation of the uPA gene and its possible role in mediating the aggressive biology of pancreatic cancer. This disease is the ®fth leading cause of cancer death with an overall 5-year survival rate of less than 5% (DiGiuseppe et al., 1996; Rosewicz and Wiedenmann, 1997) , and has the worst prognosis of all gastrointestinal malignancies. Most patients develop hepatic metastasis and die secondary to the deleterious physiologic eects of progressive metastatic disease. Current therapy has little eect on the development or growth of metastases. Therefore, it is important to understand the mechanism of pancreatic cancer metastasis and develop strategies to improve therapeutic response.
We reported that RelA was constitutively activated in pancreatic adenocarcinoma and that the constitutive activity of RelA was inhibited by dominant-negative mutants of IkBa, ras, and MEKK1 (Wang et al., 1999) . These results show that MAP kinase signaling cascades are key components regulating RelA in pancreatic adenocarcinoma cells. However, downstream target genes of RelA that are relevant to tumorigenesis and tumor metastasis remain unclear. Interestingly, Hansen et al. (1992) had reported that phorbol ester-inducible uPA expression was mediated by two NF-kB heterodimeric binding complexes. One consisted of Rel/p65 and the other p65/p50. We therefore undertook a study to de®ne the expression of uPA in pancreatic adenocarcinoma cells and to determine whether uPA expression is induced by constitutive RelA activity in this cancer. As shown in this report, we found that: (1) uPA was overexpressed in pancreatic adenocarcinoma tissue and cell lines; (2) uPA overexpression was induced by constitutive RelA activity in pancreatic adenocarcinoma cells; and (3) inhibition of constitutive RelA activity suppressed uPA expression in pancreatic adenocarcinoma cell lines.
Results
uPA is overexpressed in pancreatic adenocarcinoma and pancreatic tumor cell lines, and its expression is related to tumor metastatic potential To determine the level of uPA protein in pancreatic adenocarcinoma, paran sections of 30 human pancreatic adenocarcinoma samples and ®ve normal pancreatic tissue samples were subjected to immunohistochemical analysis with anity-puri®ed anti-human uPA monoclonal antibody. Speci®c uPA staining was detected in 83% of (25 of 30) pancreatic adenocarcinomas but no staining was detected in normal human pancreatic ductal epithelial cells (Figure 1 ). No nonspeci®c binding or cross reactivity of this antibody to other proteins were detected in subsequent Western blot analysis (data not shown). These results suggested that overexpression of uPA may contribute to the metastatic potential of human adenocarcinoma.
To further examine the overexpression of uPA in human pancreatic adenocarcinoma, levels of uPA mRNA and protein in pancreatic adenocarcinoma cell lines were studied. Northern blot analysis was carried out using RNA extracted from 11 pancreatic cell lines. Figure 2 shows that MiaPaCa-2, Hs-766T, CFPAC-1, CAPAN-2, MDAPanc48, MDAPanc28, MDAPanc3 and Panc-1 exhibited much higher levels of uPA mRNA, compared to BxPC-3, AsPC-1 and CAPAN-1 cells that displayed low levels of uPA mRNA. The percentage of pancreatic adenocarcinoma cell lines with high level of uPA mRNA (73%, eight of 11) is consistent with the results obtained from the immunohistochemical analysis of pancreatic tumor tissues. The high-and low-uPA expressing pancreatic tumor cell lines provided useful tools for studying the regulation of uPA expression. To further analyse the level of uPA protein and enzymatic activity, four human pancreatic tumor cell lines (CFPAC-1, BxPC-3, AsPC-1 and CAPAN-1) representing dierent levels of uPA expression were chosen for subsequent analyses. Cytoplasmic extracts from those four cell lines were prepared for Western blot analysis. As shown in Figure 3a , the cytoplasmic uPA protein level in CFPAC-1 cells was much higher relative to BxPC-3, AsPC-1 and CAPAN-1 cells. Using these four cell lines, Western blot analysis was also carried out to determine the level of secreted uPA in conditioned media collected from cultures of equal numbers of cells. As shown in Figure 3b , conditioned medium from CFPAC-1 cells had the highest uPA level at 24 and 48 h; an intermediate level of uPA activity was observed in conditioned medium from BxPC-3 cells, and the lowest levels of uPA were detected in conditioned media from AsPC-1 and CAPAN-1 cells.
To determine the uPA enzymatic activity secreted by these four pancreatic cell lines, zymography, with casein and plasminogen as the in-gel substrate, was carried out using the conditioned medium collected from cultures of equal numbers of cells. uPA activity was demonstrated as an unstained band in the Coomassie blue-stained gel. As shown in Figure 3c , CFPAC-1 cells had the highest level of uPA activity, BxPC-3 cells had an intermediate level and AsPC-1 and CAPAN-1 cells had a very low level of proteolytic activity. Taken together, these results indicate that uPA was overexpressed with very potent enzymatic activity in CFPAC-1 cells, that the uPA protein level and activity in BxPC-3 cells was intermediate, and that in AsPC-1 and CAPAN-1 cells both the uPA protein level and uPA activity were almost undetectable. The expression patterns of uPA mRNA, cytoplasmic and secreted uPA protein and uPA enzyme activity were consistent in these analyses.
To determine whether high expression and activity of uPA contributed to the invasive and metastatic potential of pancreatic tumor cells, we performed adhesion assays using the high-and low-uPA-expressing pancreatic tumor cell lines CFPAC-1 and CAPAN-1, respectively. As shown in Figure 3d , the numbers of CAPAN-1 cells that adhered to laminincoated plates were four times the numbers of CFPAC-1 cells that adhered. Similar adhesion pro®les were observed on ®bronectin-and collagen-coated plates:
Figure 2 uPA mRNA level in pancreatic adenocarcinoma cell lines. Total RNA (10 mg) extracted from dierent cell lines was subjected to Northern analysis. The blots were hybridized with radioisotope 32 P-dCTP-labeled human the 1.2-kb PstI uPA cDNA probe, exposed, stripped, and rehybridized with the cDNA probe for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for loading control CAPAN-1 cells showed much more adhesiveness to ®bronectin and collagen than did CFPAC-1 cells ( Figure 3d ). Taken together, these data show that overexpression of the uPA gene decreased the capabilities of pancreatic cancer cells to adhere to extracellular matrix and basement membrane, suggesting that of uPA overexpression plays a critical role in the invasive and metastatic potential of pancreatic adenocarcinoma.
Overexpression of uPA is induced transcriptionally
To determine whether the overexpression of uPA is caused by uPA gene ampli®cation or by transcriptional up-regulation, we carried out Southern blot and nuclear run-on analyses. The Southern blot analysis using DNA from human normal pancreas as a control showed that the overexpression of uPA in these cell lines did not result from uPA gene ampli®cation suggesting that overexpression of uPA may be regulated at the transcriptional level ( Figure 4a ). Nuclei from CFPAC-1 and CAPAN-1 cells were isolated, and a nuclear run-on assay was performed to compare the RNA transcription rates of these two cell lines. The results of nuclear run-on assay clearly indicated that overexpression of uPA in CFPAC-1 cells resulted from transcriptional up-regulation ( Figure 4b ).
Transcription factor RelA plays an important role in regulating uPA expression in pancreatic adenocarcinoma cells
We previously showed that the transcription factor RelA was constitutively activated in pancreatic adenocarcinoma tissue samples and cell lines (Wang et al., 1999) . It has been reported that the kB enhancer element between 71592 bp and 71570 bp of the uPA promoter mediated phorbol ester-inducible urokinase gene expression and the kB binding complexes consist of Rel/p65 and p65/p50. (Hansen et al., 1992) . We undertook the following studies to speci®cally determine the possible role of constitutive RelA activity in inducing uPA gene overexpression in pancreatic cancer cells.
In Figure 5 (lane 1), electromobility shift assay using a probe containing the uPA kB site con®rmed the constitutive RelA activity in CFPAC-1 cells. The speci®city of RelA DNA binding activity was determined by competition with double-stranded oligonucleotides containing mutant (mu) or wildtype (wt) uPA kB site and HIV wild-type kB site ( Figure 5 , lanes 2 ± 6). To con®rm that the uPA kB binding complex consists of RelA/p50, supershift experiments were performed with anti-RelA (p65), anti-p50, and anti c-Rel antibodies. The results showed that RelA and p50 were present in the uPA kB binding complex, but c-Rel protein could not be detected in the uPA kB binding complex ( Figure 5 , lanes 7 ± 9). These data are consistent with our previous report that constitutive kB binding activity in pancreatic adenocarcinoma tissue samples and cell lines contained RelA(p65)/p50 proteins (Wang et al., 1999) . To determine whether the RelA protein can activate the kB binding element in the uPA promoter, RelA (p65) expression vectors, HIV kB-CAT reporter plasmids containing wild-type or mutant kB sites (Chiao et al., 1994) , a uPAwtkB- CAT reporter plasmid (Hansen et al., 1992; Lengyel et al., 1995c ) and a uPAmukB-CAT reporter plasmid were cotransfected into AsPC-1 cells that express much lower level of uPA in comparison with that in CFPAC-1 cells (Figure 2 ) and have constitutive RelA activity (Wang et al., 1999) . CAT assay results showed that constitutive RelA activity in AsPC-1 cells activated the HIVwtkB-CAT reporter gene (Figure 6a, lane 3) and overexpression of RelA by transient transfection did not signi®cantly increase the HIVwtkB-CAT reporter gene activity (Figure 6a , lane 4). Little reporter gene activity was detected when the HIVmukB-CAT was used (Figure 6a , lanes 1 and 2). In Figure 6b, (Figure 6b lanes 1 and 2) by 250% over the control and was consistently obtained in three independent experiments. However, the similar basal levels of CAT activities between the 2-kb uPA(wt)kB promoter-and 2-kb uPA(mu) kB promoter-CAT reporter gene constructs that were consistently obtained in three independent experiments may be due to other endogenous transcription factors such as c-Jun or Ets-1 and Ets-2 (Janulis et al., 1999; Watabe et al., 1998) . In contrast, overexpression of RelA increased uPA[mu]kB-CAT reporter gene activity to a much lesser extent (70%, Figure 6b lanes 3 and 4). The small increase seen with the uPA[mu]kB-CAT reporter gene may be due to the persistent weak interaction of overexpressed RelA with seven out of 10 remaining wild-type nucleotides in the mutated kB site in the uPA promoter. Nevertheless, these results demonstrate that the kB site in uPA promoter is the major determinant for the enhanced expression seen in the presence or overexpressed RelA in the transient transfection experiments. To con®rm that the overexpression of the uPA gene in pancreatic tumor cells was speci®cally induced by constitutive RelA, the plasmids expressing dominant-negative IkBa(IkBaM) (Van Antwerp et al., 1996) were included in cotransfection experiments using CFPAC-1 cells that express high level of uPA (Figures 2 and 3 ) and RelA activity (Wang et al., 1999) . The phosphorylation mutant of IkBa(IkBaM) was generated by converting the inducible phosphorylation sites of serine 32 and 36 (which are responsible for NF-kB activation) to alanines. The carboxyl-terminal phosphorylation sites in the PEST sequence implicated in constitutive turnover of IkBa, were also mutated (Van Antwerp et al., 1996) . It has been shown that ectopically expressed IkBaM completely inhibits kBspeci®c DNA binding activity in extracts from cell lines stimu-lated with TNFa (Van Antwerp et al., 1996) . The results show that dominant-negative IkBa eciently blocked uPA promoter activation in CFPAC-1 cells (Figure 6c ). To rule out that overexpression of IkBaM did not inhibit gene expression nonspeci®cally, we repeated the transfection experiments using a TK-Renilla luciferase reporter gene for normalization of transfection eciency, a b-actin-promoter ®re¯y luciferase reporter gene for determining the speci®city of IkBaM protein, and uPA-CAT reporter genes with wild-type and mutated kB sites for determining the inhibition of RelA activity by the IkBaM protein. The results presented in Figure 6d showed that b-actin-promoter was not aected by overexpression of IkBaM protein.
We therefore conclude that the constitutive RelA uPA overexpression can be repressed by NF-kB inhibitors TPCK (N-tosyl-L-phenylalanine chloromethyl ketone) and dexamethasone have been shown to inhibit NF-kB activation (Chiao et al., 1994; Auphan et al., 1995; Scheinman et al., 1995; Wu et al., 1996) . To further test whether RelA regulates uPA gene expression in pancreatic cells and whether uPA overexpression can be inhibited by NF-kB inhibitors, CFPAC-1 cells, which overexpress uPA and possess constitutive RelA activity, were treated with TPCK and dexamethasone. Nuclear extracts were prepared from CFPAC-1 cells with or without treatment with these NF-kB inhibitors to determine whether RelA DNA binding activity was inhibited. Simultaneously, media were collected from the CFPAC-1 cell cultures after TPCK and dexamethasone treatments to determine the levels of secreted uPA protein. As shown in Figure 7a , after treatment with TPCK and dexamethasone, RelA/NFkB DNA binding activity was clearly inhibited in the CFPAC-1 cells. The speci®c RelA/NF-kB DNA binding activity was con®rmed in the nuclear extracts of control CFPAC-1 cells by competition studies using oligonucleotides containing the wild-type (wt) or mutant (mu) NF-kB binding site and by supershifting assays using anti-RelA and anti-p50 antibodies ( Figure  5 ). Consistent with the inhibition of RelA NF-kB DNA binding activity in the nuclei of CFPAC-1 cells, levels of secreted uPA protein were reduced in conditioned media from cultures of CFPAC-1 cells treated with TPCK and dexamethasone ( Figure 7b ). Taken together, our data indicate that uPA is frequently overexpressed in pancreatic adenocarcinoma tissues and cell lines, uPA overexpression is induced by the constitutive RelA activity in pancreatic adenocarcinoma cells and inhibition of constitutive
RelA activity suppresses uPA expression in pancreatic adenocarcinoma cell lines.
Discussion
In this report, we have shown the key role played by RelA in inducing uPA gene overexpression. In turn, uPA is capable of increasing the invasion and metastatic potential of pancreatic ductal adenocarcinoma cells. Rel/NF-kB belongs to a family of pleiotropic transcription factors that control the expression of numerous genes Baltimore, 1989, Grilli et al., 1993) . The downstream target genes of Rel/NFkB include the p53 tumor suppressor gene, several proteins important to cellular adhesion (ICAM-I, ELAM-I, VCAM-I) and extracellular matrix protease (type IV collagenase) (Wu and Lozano, 1994; Ghersa et al., 1992; Iademarco et al., 1992; Voraberger et al., 1991; Whelan et al., 1991; Sato and Seiki, 1993) . A recent report showed that the promoter of the major histocompatibility complex (MHC) Class I-encoding gene contains an NF-kB site and that NF-kB p50 homodimers repress H-2Kb expression in metastatic tumor cells (Plaksin et al., 1993) . It was previously shown that downregulation of the MHC Class Iencoding gene's expression in tumors is associated with reduced immunogenicity and with the development of metastatic phenotype (Cordon-Cardo et al., 1994) . Taken together, these results suggest that dysregulation of NF-kB activity in tumor cells may play a critical role in the development of cancer metastasis. uPA plays a central role in catalyzing extracellular and basement membrane degradation. Several investigators have studied the regulation of uPA expression and they have found that induction of uPA expression is detected during G0/G1 transition and correlates with the proliferative state of normal mouse cells (Grimaldi et al., 1993) . uPA expression is required in in vitro assays of basement membrane invasion and in metastasis of model tumors and there is a strong association between uPA expression and the invasivemetastatic phenotype. High expression of uPA is a signi®cant prognostic marker for various human tumors (Blasi, 1990) . For example. uPA is a prognostic marker in breast cancers (Duy et al., 1990) . Axelrod et al. (1989) reported H-ras-transformed NIH3T3 cells stably expressing a transfected uPA gene invaded more rapidly than parent cells through a basement membrane and caused a high incidence of pulmonary metastatic lesions after intravenous injection into nude mice. Conversely, inhibition of uPA can reduce the invasion and metastasis in H-ras-transformed NIH3T3 cells (Axelrod et al., 1989; Rao et al., 1993) . It has also been reported that inhibition of uPA can reduce the size of prostate cancer tumors or even cause complete remission of cancers in SCID mice (Harvey et al., 1988; Jankun et al., 1997) . These ®ndings provide direct evidence for a causal role for uPA in local tumor invasion and metastasis. However, the role of uPA and its regulation in pancreatic cancer metastasis has not been previously reported. In this report, we have provided evidence that uPA is overexpressed in most pancreatic adenocarcinomas and is related to the metastatic potential of pancreatic tumors (Figures 1 ± 3) . The overexpression of uPA is induced transcriptionally by constitutively activated RelA activity (Figures 4 ± 6) . Inhibition of constitutive RelA activity by cotransfection with dominant-negative mutant of IkBa and by treatment with the known NF-kB inhibitors TPCK and dexamethasone represses the overexpression of uPA in pancreatic tumor cell lines (Figures 6 and 7) .
Several inducers have been reported to induce uPA promoter activity by acting at its upstream PEA3/AP1 sites and via the Ras/Raf-1/MEK/ERK pathway. These inducers include polyomavirus middle-T antigen (Besser et al., 1995a) , macrophage colony-stimulating factor (Stacey et al., 1995) , ®broblast growth factor 2 (Besser et al., 1995b) , LFB3 (Marksitzer et al., 1995) , hepatocyte growth factor (Jeers et al., 1996; Mars et al., 1996) , tumor necrosis factor-a (Lengyel et al., 1995a) , c-Ha-ras (Lengyel et al., 1995b) , cyclic adenosine monophosphate (Grimaldi et al., 1993) and tissue plasminogen activator . Recently, it was reported that MEKK1 kinase can phosphorylate the IkBa kinase complex and that CHUK is one of the IkBa kinases (Lee et al., 1997; Regnier et al., 1997; DiDonato et al., 1997) . It will be important to determine whether dominant negative mutants of CHUK, MEKK1 and other components of the MAP kinase pathway can inhibit uPA overexpression in human pancreatic tumor cells. Interestlingly, our data show that additional transcription factors may involved in overexpression of uPA in the pancreatic cancer cell lines. Previously, we have shown that RelA is constitutively activated in pancreatic adenocarcinoma cell lines CAPAN-1, ASPC-1 and CFPAC-1 (Wang et al., 1999) . Figures 2 and 3 show that the level of uPA expression in both CAPAN-1 and ASPC-1 is much lower than those in CFPAC-1 and other cell lines, suggesting that constitutive RelA activity is necessary but may not be sucient to induce uPA overexpression. It is possible that other transcription factors may cooperate with RelA protein to induce uPA overexpression in CFPAC-1 cells, whereas the activities of such transcription factors that cooperate with RelA protein to induce uPA overexpression may not present in CAPAN-1 and ASPC-1. Given the role of uPA in tumor invasion and metastasis, it will be important to identify the transcription factors that cooperate with RelA protein to induce uPA overexpression.
In this report, we also showed that uPA expression in pancreatic cell lines can be inhibited by using a dominant-negative mutant of IkBa to inhibit inducible phosphorylation in NF-kB activation or by using known NF-kB inhibitors such as TPCK and dexamethasone. Although both TPCK and dexamethasone reduced NF-kB activity to a similar level, there is a dierence in reduction of the levels of uPA between TPCK and dexamethasone treated cells. This dierence may re¯ect a nonspeci®c eect or the high toxicity of TPCK. These known uPA inhibitors are unlikely to be used in anticancer therapy because of their weak inhibitory activity or high toxicity. Thus, these ®ndings may help guide studies in which dierent NF-kB inhibitors are analysed for their ability to prevent liver metastasis of pancreatic cancer in animal models by inhibiting overexpression of uPA.
Materials and methods

Cell lines and cell culture
The human pancreatic adenocarcinoma cell lines AsPC-1, BxPC-3, CAPAN-1, CAPAN-2, Hs-766T, CFPAC-1, Panc-1 and MiaPaCa-2 were obtained from the American Type Cell Culture (Rockville, MD, USA). MDAPanc-3, MDAPanc-28 and MDAPanc-48 cells were obtained from Dr Marsha L Frazier (MD Anderson Cancer Center). All cells were grown in 10% fetal bovine serum in Dulbecco's modi®ed Eagle's medium in a 378C incubator containing a 5% CO 2 atmosphere.
Immunohistochemistry
Formalin-®xed, paran-embedded adenocarcinoma tissues were obtained at the time of pancreatectomy from patients at our institution. The monoclonal anti-human uPA antibody was purchased from American Diagnostica (Greenwich, CT, USA). Immunohistochemical staining was performed as described previously (Sinicrope et al., 1996) .
Western blotting and zymography
Conditioned media were collected from cultures containing equal numbers of cells. Cytoplasmic extracts were prepared as described by Andrews and Faller (1991) . The amount of urokinase in cytoplasm and conditioned medium was determined by Western blotting. Samples were denatured in the absence of reducing agent and subjected to 10% sodium dodecyl sulfate-polyacylamide gel electrophosesis (SDS ± PAGE). The resolved proteins were transferred to an Immobilon-P membrane (Millipore, Bedford, MA, USA). The membrane was blocked with 5% nonfat milk and incubated with polyclonal antibody to urokinase (American Diagnostica). Proteins were detected using a chemoilluminescence kit (Amersham, Arlington Heights, IL, USA). Zymography was performed as described (Gogly et al., 1998) to determine the uPA enzyme activity. Conditioned medium collected from cultures containing equal numbers of cells was denatured in the absence of reducing agent and subjected to 7.5% SDS ± PAGE on a gel containing 0.2% casein and 6 mg/ml plasminogen. The gels were incubated at 378C for 2 h in the presence of 2.5% Triton X-100 and then for 1 h in a buer containing 10 mM CaCl 2 , 0.15 M NaCl and 50 mM Tris (pH 7.5). The gel was then stained for protein with 0.25% Coomassie blue and photographed on a light box. Plasminogen-dependent proteolysis was detected as a white zone in a dark ®eld.
Adhesion assay
In vitro adhesion assays were performed as described by Weinel et al. (1995) . Cells were grown in complete medium until reaching subcon¯uence and then were detached by trypsin-EDTA (Gibco ± BRL, Gaithersburg, MD, USA; 0.05% trypsin). Cells were washed once with phosphatebuered saline and suspended in F-10 Nutrient Mixture (Ham) (Gibco ± BRL) containing 0.5% bovine serum albumin. Cell viability was determined by trypan blue exclusion to be 495%. Flat-bottom 96-well enzyme-linked immunosorbant assay (ELISA) plates (Corning, Corning, NY, USA) were coated with 10 mg/ml ®bronectin (Sigma, St. Louis, MO, USA), collagen type IV (Sigma) or laminin (Sigma), or 10 mg/ml BSA or 100% serum overnight at 48C. The wells were washed twice and blocked with 1 ± 5% BSA in PBS for 2 h at 378C. After removal of BSA, 1610 5 of CFPAC-1 and CAPAN-1 cells were seeded into each well of the 96-well plate. Attachment was allowed for 1 h at 378C. Nonadherent cells were carefully removed by washing three times with PBS. Adherent cells were ®xed and stained with 0.1% crystal violet for 5 min. Cell density was determined by uPA gene regulation by NF-kB in pancreatic cancer W Wang et al measuring the absorbance at 630 nm on an ELISA reader (Scimetrics Inc., USA). Actual cell numbers were determined by normalizing dye uptake values with a calibration curve.
Northern and Southern blotting
Total RNA was isolated from the pancreatic cancer cell lines by the acid guanidium thiocyanate phenol chloroform (AGPC) extraction (Chomczynski and Sacchi, 1987) . Ten micrograms of total RNA was subjected to electrophoresis in 1% denaturing agarose gels, transferred to nylon membranes (Stratagene, La Jolla, CA, USA) and ultraviolet radiationcrosslinked and baked. The membranes were hybridized with 32 P-dCTP-labeled 1.2-kb PstI uPA cDNA fragment and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA probes.
Genomic DNA was prepared from pancreatic cell lines according to the method described by Sambrook et al. (1989) , digested to completion with an excess amount of EcoRI enzymes and then run in a 0.8% agarose gel. Southern blotting was then performed as described (Sambrook et al., 1989) . The 1.2-kb PstI uPA cDNA fragment was used as probe in Southern blot analyses.
Nuclear run-on assay
Nuclear run-on assay was performed as described (McKnight and Palmiter, 1979; Groudine et al., 1981; Murdoch et al., 1982) . Cells (1610 8 ) were harvested and washed with PBS and resuspended in a hypotonic buer containing 10 mM HEPES, pH 7.9, 0.75 mM spermidine, 0.15 mM spermine, 0.1 mM EDTA, 0.1 mM ethylene glycol-bis (b-aminoethyl ether) N,N,N'-tetraacetic acid (EGTA), 1 mM DL-dithiothreitol (DTT) and 0.5% Nonidet P-40. The cells were lysed in a Dounce homogenizer. After centrifugation, the nuclear pellets were resuspended in transcription buer (150 mM KCl, 5 mM MgCl 2 , 1 mM MnCl 2 , 20 mM HEPES, pH 7.9, 10% glycerol and 5 mM DTT). Nuclei were incubated at 208C for 30 min in the presence of 1 mM each adenosine triphosphate (ATP), guanidine triphosphate (GTP) and cytidine triphosphate (CTP) and 200 mCi [ 32 P]deoxyuridine triphosphate. Nuclei were then collected and treated twice with deoxyribonuclease (DNase) I and proteinase K. RNA was extracted with phenol/chloroform and precipitated. Radioactive RNA was treated again with DNase I and proteinase K followed by phenol/chloroform extraction. Newly transcribed RNA (6610 7 c.p.m./reaction) was incubated at 428C for 48 h with nylon-immobilized cDNAs (3 mg/mm 2 ) corresponding to uPA, GAPDH and linearized plasmid vector. After hybridization, the ®lter was washed at 658C with 0.16SSC in the presence of 1% SDS and exposed on X-ray ®lm.
Nuclear extracts and electrophoretic mobility shift assay (EMSA) Nuclear extracts were prepared by the method of Andrews and Faller (1991) . After preparations 5 mg of nuclear extract was incubated with 1 mg of poly(dI-dC) (Pharmacia) in 10 ml of binding buer (75 mM NaCl, 15 mM Tris-HCl, pH 7.5, 1.5 mM EDTA, 1.5 mM DTT, 25% glycerol and 20 mg/ml BSA) for 30 min at 48C. 32 P-labeled doublestranded oligonucleotides containing the kB site (underlined) found in the Igk gene (5'-CTCAACAGAGGG-GACTTTCCGAGAGGCCAT) were incubated as probes. Unlabeled double-stranded oligonucleotides (50-fold molar excess) containing the Igk wild-type kB site and mutant kB site (5' -CTCAACAGAGTTGACTTTCGAGAGGCCAT -3') (Chiao et al., 1994) were used for competition studies. For antibody supershifts, 2 ml of the polyclonal antibodies against p65 and p50 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were preincubated for 30 min at room temperature before probe was added. The probe was allowed to bind for 20 min at room temperature. Reaction mixtures were analysed on 4% polyacrylamide gels containing 0.256TBE (22.5 mM Tris, 22.5 mM borate, 0.5 mM EDTA, pH 8.0) buer.
Site-directed mutagenesis
By using PCR-mediated site-directed mutagenesis, the wildtype kB element (5'-GGGAAAGTC-3') in uPA-CAT reporter gene were substituted with a mutant kB site (5'-CGGAAAATT-3' where underlined bases are the mutated sequences). PCR-mediated site-directed mutagenesis were performed using double-stranded, site-directed mutagenesis kit from Stratagene (La Jolla, CA, USA).
Transient transfections, CAT assays and dual luciferase assay
Transient transfection was performed as described previously (Chiao et al., 1994) . Brie¯y, 1 ± 2 mg of the wild-type (HIV[wt]CAT), or mutant (HIV[mu]CAT) kB plasmid that contains two kB sites derived from the HIV long terminal repeat region (30 bp) and the TATA box region of the TK gene in the promoter the CAT reporter construct, or CAT reporter plasmid driven by 2345 bp of uPA promoter (uPAwtkBcat) (Hansen et al., 1992; Lengyel et al., 1995a) or (uPAmukBcat) and 5 or 10 mg of NF-kB expression plasmids (CMV-p65) (Chiao et al., 1994) or expression plasmid of dominant-negative IkBa (CMV-IkBaM) (Van Antwerp et al., 1996) were cotransfected into AsPC-1 or CFPAC-1 cells with 1 ± 5 mg of b-actin LacZ, or b-actin Fire¯y-luciferase and TK-Rellina luciferase reporter genes. Forty-eight hours after transfection, cells were harvested and the CAT reaction was performed as previously described (Chiao et al., 1994) . Brie¯y, the relative transfection eciencies were determined by using the cotransfected LacZ expression plasmid (1 mg, b-actin-LacZ), and subsequent bgalactosidase activities in the cell extracts were used to normalize the transfection eciencies. Luciferase assay was performed using Dual-Luciferase TM Reporter Assay System (Promega) and according to the instruction from the manufacturer.
